<p>赫龙治疗公司（NASDAQ:HRTX - 获取免费报告）的股票被目前覆盖该公司的五家评级机构一致推荐为 “持有”，Marketbeat 报道称。一位投资分析师给予该股票卖出评级，一位给予持有评级，三位给予买入评级。在过去一年中更新了对该股票覆盖的分析师的平均 12 个月目标价为 4.50 美元。</p>
<p>HRTX 已成为几份研究报告的主题。华尔街禅在 8 月 9 日（星期六）的一份研究报告中将赫龙治疗公司的股票评级从 “买入” 下调至 “持有”。Needham &amp; Company LLC 在 8 月 8 日（星期五）的一份研究报告中将赫龙治疗公司的股票目标价从 4.00 美元下调至 3.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了赫龙治疗公司的股票 “卖出（e+）” 评级。杰富瑞金融集团在星期二的一份研究报告中重申了赫龙治疗公司的股票 “买入” 评级。最后，Zacks Research 在 10 月 7 日（星期二）的一份研究报告中将赫龙治疗公司的股票评级从 “强烈卖出” 上调至 “持有”。</p>
<p>获取 <strong>赫龙治疗</strong> 的提醒：</p>
<p><strong>查看我们关于赫龙治疗的最新报告</strong></p>
<h2>赫龙治疗的内部买卖</h2>
<p>在其他新闻中，主要股东 Rubric Capital Management Lp 于 8 月 8 日（星期五）收购了 2387225 股该公司的股票。该股票的平均购买成本为每股 1.50 美元，总交易额为 3580837.50 美元。收购完成后，内部人士直接持有该公司 29100728 股股票，价值 43651092 美元。此次交易使其持股增加了 8.94%。该收购在向 SEC 的备案中披露，相关信息可通过 SEC 网站访问。此外，董事亚当·摩根在 8 月 8 日（星期五）的一笔交易中购买了 1766546 股赫龙治疗的股票。该股票的平均购买价格为每股 1.50 美元，总价值为 2649819.00 美元。收购完成后，该董事直接持有该公司 8753290 股股票，价值 13129935 美元。这代表其持股增加了 25.28%。该购买的披露信息可在 SEC 备案中找到。5.86% 的股票由内部人士持有。</p>
<h2>机构投资者对赫龙治疗的看法</h2>
<p>一些大型投资者最近买入和卖出了 HRTX 的股票。先锋集团在第一季度将其在赫龙治疗公司的股份提高了 0.8%。先锋集团目前持有 8225585 股生物技术公司的股票，价值 18096000 美元，此前在上个季度购买了 67976 股。Tejara Capital Ltd 在第三季度将其在赫龙治疗公司的股份增加了 1.6%。Tejara Capital Ltd 目前持有 4589715 股生物技术公司的股票，价值 5783000 美元，此前在此期间购买了 72300 股。Geode Capital Management LLC 在第二季度将其在赫龙治疗公司的股份增加了 14.6%。Geode Capital Management LLC 目前持有 3566813 股生物技术公司的股票，价值 7385000 美元，此前在此期间收购了 453085 股。AIGH Capital Management LLC 在第二季度将其在赫龙治疗公司的股份增加了 8.3%。AIGH Capital Management LLC 目前持有 3009257 股生物技术公司的股票，价值 6229000 美元，此前在此期间收购了 231057 股。最后，Marshall Wace LLP 在第二季度将其在赫龙治疗公司的股份增加了 130.7%。Marshall Wace LLP 目前持有 2894072 股生物技术公司的股票，价值 5991000 美元，此前在此期间收购了 1639376 股。对冲基金和其他机构投资者持有该公司 80.01% 的股票。</p>
<h2>赫龙治疗的价格表现</h2>
<p>在周二的午盘交易中，NASDAQ HRTX 下跌 0.04 美元，达到 1.14 美元。该股票的交易量为 5679439 股，而其平均交易量为 1692648 股。赫龙治疗的股价在过去一年中最低为 1.04 美元，最高为 2.68 美元。该股票的 50 日简单移动平均为 1.27 美元，200 日简单移动平均为 1.70 美元。该股票的市值为 2.0898 亿美元，市盈率为-57.00，贝塔值为 1.25。</p>
<p>赫龙治疗（NASDAQ:HRTX - 获取免费报告）最近于 8 月 8 日（星期五）发布了其财报。该生物技术公司报告本季度每股收益为（0.02 美元），低于分析师一致预期的（0.01 美元）0.01 美元。该业务本季度的收入为 3720 万美元，而分析师预期为 3808 万美元。赫龙治疗已设定其 2025 财年的每股收益指导。卖方分析师预计赫龙治疗在当前财年将发布-0.13 的每股收益。</p>
<h2>关于赫龙治疗</h2>
<p>（获取免费报告）</p>
<p>赫龙治疗公司是一家商业阶段的生物技术公司，专注于通过开发和商业化治疗来改善患者的生活，从而增强医疗护理。该公司的产品候选者利用其专有的 Biochronomer 药物递送技术，该技术能够在几天到几周的时间内通过一次给药提供一系列短效药物的治疗水平。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票胜过赫龙治疗</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>D-Wave 财报中需要关注的 3 种潜在情景</li>
<li>现在购买的 3 只最佳金融科技股票</li>
<li>艾利·莉莉发布出色的第三季度：长期上涨潜力显著</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>优步击败了 Lyft——而且差距不小</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Heron Therapeutics 吗？</h2>
<p>在考虑 Heron Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Heron Therapeutics 并不在名单上。</p>
<p>虽然 Heron Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HRTX

<p>Heron Therapeutics, Inc.（纳斯达克代码：HRTX）获得了五家券商的共识评级为 “持有”。一位分析师将其评级为卖出，一位评级为持有，三位评级为买入，12 个月的平均目标价为 4.50 美元。近期内部交易包括主要股东 Rubric Capital Management 收购 239 万股，以及董事 Adam Morgan 购买 177 万股，均以每股 1.50 美元的价格进行。目前该股票的交易价格为 1.14 美元，市值为 2.0898 亿美元，市盈率为-57.00</p>

<p>Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) have been assigned a consensus recommendation of &#34;Hold&#34; from the five ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $4.50.</p>
<div class="lb-trans"><p>赫龙治疗公司（NASDAQ:HRTX - 获取免费报告）的股票被目前覆盖该公司的五家评级机构一致推荐为 “持有”，Marketbeat 报道称。一位投资分析师给予该股票卖出评级，一位给予持有评级，三位给予买入评级。在过去一年中更新了对该股票覆盖的分析师的平均 12 个月目标价为 4.50 美元。</p>
</div><p>HRTX has been the subject of several research reports. Wall Street Zen lowered shares of Heron Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 9th. Needham &amp; Company LLC reduced their price objective on shares of Heron Therapeutics from $4.00 to $3.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, August 8th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th. Jefferies Financial Group reiterated a &#34;buy&#34; rating on shares of Heron Therapeutics in a research note on Tuesday. Finally, Zacks Research upgraded shares of Heron Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, October 7th.</p>
<div class="lb-trans"><p>HRTX 已成为几份研究报告的主题。华尔街禅在 8 月 9 日（星期六）的一份研究报告中将赫龙治疗公司的股票评级从 “买入” 下调至 “持有”。Needham &amp; Company LLC 在 8 月 8 日（星期五）的一份研究报告中将赫龙治疗公司的股票目标价从 4.00 美元下调至 3.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了赫龙治疗公司的股票 “卖出（e+）” 评级。杰富瑞金融集团在星期二的一份研究报告中重申了赫龙治疗公司的股票 “买入” 评级。最后，Zacks Research 在 10 月 7 日（星期二）的一份研究报告中将赫龙治疗公司的股票评级从 “强烈卖出” 上调至 “持有”。</p>
</div><p>Get <strong>Heron Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>赫龙治疗</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on Heron Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于赫龙治疗的最新报告</strong></p>
</div><h2>Insider Buying and Selling at Heron Therapeutics</h2>
<div class="lb-trans"><h2>赫龙治疗的内部买卖</h2>
</div><p>In other news, major shareholder Rubric Capital Management Lp acquired 2,387,225 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $3,580,837.50. Following the completion of the acquisition, the insider directly owned 29,100,728 shares of the company's stock, valued at $43,651,092. The trade was a 8.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Adam Morgan bought 1,766,546 shares of Heron Therapeutics stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $1.50 per share, with a total value of $2,649,819.00. Following the completion of the acquisition, the director directly owned 8,753,290 shares of the company's stock, valued at $13,129,935. This represents a 25.28% increase in their position. The disclosure for this purchase is available in the SEC filing. 5.86% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，主要股东 Rubric Capital Management Lp 于 8 月 8 日（星期五）收购了 2387225 股该公司的股票。该股票的平均购买成本为每股 1.50 美元，总交易额为 3580837.50 美元。收购完成后，内部人士直接持有该公司 29100728 股股票，价值 43651092 美元。此次交易使其持股增加了 8.94%。该收购在向 SEC 的备案中披露，相关信息可通过 SEC 网站访问。此外，董事亚当·摩根在 8 月 8 日（星期五）的一笔交易中购买了 1766546 股赫龙治疗的股票。该股票的平均购买价格为每股 1.50 美元，总价值为 2649819.00 美元。收购完成后，该董事直接持有该公司 8753290 股股票，价值 13129935 美元。这代表其持股增加了 25.28%。该购买的披露信息可在 SEC 备案中找到。5.86% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Heron Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对赫龙治疗的看法</h2>
</div><p>A number of large investors have recently bought and sold shares of HRTX. Vanguard Group Inc. raised its stake in Heron Therapeutics by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 8,225,585 shares of the biotechnology company's stock valued at $18,096,000 after purchasing an additional 67,976 shares during the last quarter. Tejara Capital Ltd grew its holdings in shares of Heron Therapeutics by 1.6% during the 3rd quarter. Tejara Capital Ltd now owns 4,589,715 shares of the biotechnology company's stock worth $5,783,000 after purchasing an additional 72,300 shares during the period. Geode Capital Management LLC boosted its holdings in Heron Therapeutics by 14.6% during the 2nd quarter. Geode Capital Management LLC now owns 3,566,813 shares of the biotechnology company's stock valued at $7,385,000 after acquiring an additional 453,085 shares during the period. AIGH Capital Management LLC boosted its holdings in Heron Therapeutics by 8.3% during the 2nd quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company's stock valued at $6,229,000 after acquiring an additional 231,057 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Heron Therapeutics by 130.7% during the 2nd quarter. Marshall Wace LLP now owns 2,894,072 shares of the biotechnology company's stock valued at $5,991,000 after acquiring an additional 1,639,376 shares during the period. Hedge funds and other institutional investors own 80.01% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近买入和卖出了 HRTX 的股票。先锋集团在第一季度将其在赫龙治疗公司的股份提高了 0.8%。先锋集团目前持有 8225585 股生物技术公司的股票，价值 18096000 美元，此前在上个季度购买了 67976 股。Tejara Capital Ltd 在第三季度将其在赫龙治疗公司的股份增加了 1.6%。Tejara Capital Ltd 目前持有 4589715 股生物技术公司的股票，价值 5783000 美元，此前在此期间购买了 72300 股。Geode Capital Management LLC 在第二季度将其在赫龙治疗公司的股份增加了 14.6%。Geode Capital Management LLC 目前持有 3566813 股生物技术公司的股票，价值 7385000 美元，此前在此期间收购了 453085 股。AIGH Capital Management LLC 在第二季度将其在赫龙治疗公司的股份增加了 8.3%。AIGH Capital Management LLC 目前持有 3009257 股生物技术公司的股票，价值 6229000 美元，此前在此期间收购了 231057 股。最后，Marshall Wace LLP 在第二季度将其在赫龙治疗公司的股份增加了 130.7%。Marshall Wace LLP 目前持有 2894072 股生物技术公司的股票，价值 5991000 美元，此前在此期间收购了 1639376 股。对冲基金和其他机构投资者持有该公司 80.01% 的股票。</p>
</div><h2>Heron Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>赫龙治疗的价格表现</h2>
</div><p>NASDAQ HRTX traded down $0.04 during mid-day trading on Tuesday, reaching $1.14. 5,679,439 shares of the stock were exchanged, compared to its average volume of 1,692,648. Heron Therapeutics has a one year low of $1.04 and a one year high of $2.68. The stock has a 50 day simple moving average of $1.27 and a 200-day simple moving average of $1.70. The stock has a market cap of $208.98 million, a P/E ratio of -57.00 and a beta of 1.25.</p>
<div class="lb-trans"><p>在周二的午盘交易中，NASDAQ HRTX 下跌 0.04 美元，达到 1.14 美元。该股票的交易量为 5679439 股，而其平均交易量为 1692648 股。赫龙治疗的股价在过去一年中最低为 1.04 美元，最高为 2.68 美元。该股票的 50 日简单移动平均为 1.27 美元，200 日简单移动平均为 1.70 美元。该股票的市值为 2.0898 亿美元，市盈率为-57.00，贝塔值为 1.25。</p>
</div><p>Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Friday, August 8th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The business had revenue of $37.20 million for the quarter, compared to analysts' expectations of $38.08 million. Heron Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>赫龙治疗（NASDAQ:HRTX - 获取免费报告）最近于 8 月 8 日（星期五）发布了其财报。该生物技术公司报告本季度每股收益为（0.02 美元），低于分析师一致预期的（0.01 美元）0.01 美元。该业务本季度的收入为 3720 万美元，而分析师预期为 3808 万美元。赫龙治疗已设定其 2025 财年的每股收益指导。卖方分析师预计赫龙治疗在当前财年将发布-0.13 的每股收益。</p>
</div><h2>About Heron Therapeutics</h2>
<div class="lb-trans"><h2>关于赫龙治疗</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.</p>
<div class="lb-trans"><p>赫龙治疗公司是一家商业阶段的生物技术公司，专注于通过开发和商业化治疗来改善患者的生活，从而增强医疗护理。该公司的产品候选者利用其专有的 Biochronomer 药物递送技术，该技术能够在几天到几周的时间内通过一次给药提供一系列短效药物的治疗水平。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Heron Therapeutics</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>3 Potential Scenarios to Watch for in D-Wave's Earnings Report</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Uber Is Crushing Lyft—And It’s Not Even Close</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票胜过赫龙治疗</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>D-Wave 财报中需要关注的 3 种潜在情景</li>
<li>现在购买的 3 只最佳金融科技股票</li>
<li>艾利·莉莉发布出色的第三季度：长期上涨潜力显著</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>优步击败了 Lyft——而且差距不小</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=HRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Heron Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Heron Therapeutics 吗？</h2>
</div><p>Before you consider Heron Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Heron Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Heron Therapeutics 并不在名单上。</p>
</div><p>While Heron Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Heron Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Heron Therapeutics, Inc.（纳斯达克股票代码：HRTX）被券商给予 “持有” 评级的平均评价